LYMPHOMAS

A phase 2 clinical trial has demonstrated the potential of zanubrutinib combined with R-CHOP for the treatment of untreated diffuse large B-cell lymphoma with extranodal involvement.

SLS009 showed promising efficacy in a phase 1 trial and now has been granted a fast track designation by the FDA for the treatment of relapsed or refractory peripheral T-cell lymphoma.

At a live, virtual event, Farrukh Awan, MD, provided commentary on the current treatment algorithm for patients with relapsed/refractory diffuse large B-cell lymphoma and where the use of the combination regimen tafasitamab and lenalidomide fits in.

In a phase 2 study, frontline bortezomib, rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, and cytarabine hydrochloride was well tolerated in patients with B-cell non-Hodgkin marginal zone lymphoma.

Cyrus M. Khan, MD, discusses the eligibility criteria of a phase 1/2 study evaluating glofitamab for the treatment of patients with large B-cell lymphoma, and provides data from the expansion cohorts of the trial.

The CAR-HEMATOTOX score was positively associated with identifying the risk of poor treatment outcomes for patients with mantle cell lymphoma treated with chimeric antigen receptor T-cell therapy.

Patients who are currently benefiting from lacutamab may continue to receive the treatment while the clinical hold is in place.

For large cell lymphomas, physicians typically use CT and positron emission tomography-computed tomography scans to look for signs of minimum residual disease when treatment is completed.

Cyrus M. Khan, MD, discusses the phase 1/2 trial of glofitamab for use as a treatment option for patients with relapsed/refractory large B-cell lymphoma.

For World Lymphoma Awareness Day, Yuliya P.L. Linhares, MD, discusses how novel therapies are changing the approach to treatment for this patient population.

The combination of AFM13 with AlloNK has been granted FDA fast track designation and is being investigated in the phase 2 LuminICE-203 study for patients with Hodgkin lymphoma.

Preclinical data of soquelitinib has demonstrated tumor responses in difficult to treat T-cell malignancies. The agent will now be evaluated in a phase 3 study in relapsed peripheral T cell lymphoma.

Despite complete remission rates of up to 90%, late toxicities, such as secondary malignancies and cardiovascular events, are key concerns in patients treated for early-stage Hodgkin lymphoma.

Although chemotherapy has represented the standard therapeutic modality for indolent non-Hodgkin lymphoma, monoclonal antibodies, immunomodulatory agents, targeted agents, bispecific antibodies, and cellular therapies are now available.

The diffuse large B-cell lymphoma treatment landscape is evolving with Pola-R-CHP and CAR T-cell therapy moving into the frontline setting.

Following positive results from the phase 1/2 EPCORE NHL-1 trial, epcoritamab is currently under evaluation across different lines of therapy and in various combinations for diffuse large B-cell lymphoma.

Data points to the loss of predictive value of an interim PET2 scan for patients with Hodgkin lymphoma when treated with a regimen containing brentuximab vedotin.

Relapsed/refractory DLBCL is associated with poor prognosis, but preclinical data suggest that adding rituximab to CD19-directed therapy such as loncastuximab tesirine may extend the duration of disease control.

Guidance from the FDA has provided a clear pathway and requested no additional efficacy or safety trials for the resubmission of the biologics license application for denileukin diftitox in cutaneous T-cell lymphoma.

Currently, CT/PET scans are primarily used for staging, response assessment, and surveillance, but these modalities have several limitations.

The combination of ibrutinib with chemoimmunotherapy improved the duration of response for a subset of patients with relapsed follicular lymphoma and marginal zone lymphoma.

Fadraciclib, a highly selective inhibitor of CDK2 and CDK9, is being investigated in clinical trials for patients with solid tumors and hematologic malignancies.

Michael T. Tees, MD, discusses the data behind ALLO-501A, an allogeneic chimeric antigen receptor T-cell therapy for relapsed or refractory large B-cell lymphoma.

During the plenary session of the 2023 American Society of Clinical Oncology Annual Meeting, we learned that BV-AVD’s reign at the top may be short lived.

Although no safety or efficacy issues were reported in the biologics license application for denileukin diftitox for cutaneous T-cell lymphoma, a complete response letter has been issued.

Investigators do not believe the benefit-risk profile of Lonca R in previously untreated diffuse large B-cell lymphoma supports continuation of the LOTIS-9 trial.

Based on promising data from the dose-escalation portion of the phase 1 ANTLER trial evaluating CB-010 in patients with B-cell non-Hodgkin lymphoma, the dose-expansion portion has initiated enrollment.

Following positive phase 2 results from the ROSEWOOD study, BeiGene is seeking FDA approval of zanubrutinib plus obinutuzumab for select patients with relapsed/refractory follicular lymphoma.